Frontline Insights in Multiple Myeloma Treatment

Medical experts discuss unmet needs surrounding treatment of multiple myeloma.

Experts explore the evolving goals in treating newly diagnosed patients with multiple myeloma, including balancing effective therapies, achieving MRD-negative remission, and managing toxicities.

Experts discuss challenges in induction regimens for transplant-ineligible myeloma patients, and evolving approaches, quad regimens, dynamic frailty, and upcoming trials shaping future treatment options.

Health care professionals delve into discussions on using quadruplets in multiple myeloma treatment, addressing challenges, and considerations for high-risk patients.

A panel of experts discuss leveraging real-world data in multiple myeloma treatment decisions and explore the significance, limitations, and evolving role of real-world data, shedding light on patient experiences, access to care, and treatment outcomes beyond clinical trials.

Renowned multiple myeloma specialists discuss challenges in treatment decisions, exploring real-world data's role, assessing risks in diverse populations, and interpreting cross-trial comparisons.

Experts discuss findings from real-world studies comparing DRd with VRD, emphasizing the importance of individualized dosing and supportive care, and navigate challenges in incorporating real-world data.

Experts discuss the evolving landscape of multiple myeloma treatment, exploring real-world evidence's role in shaping the future and its impact on clinical decisions, rare subgroups, and treatment sequencing.

Health care professionals review the 2023 American Society of Hematology Annual Meeting and Exposition (ASH 2023) multiple myeloma revelations, spotlighting transformative trials, groundbreaking translational research, and clinical perspectives that illuminate the evolving treatment landscape.

Experts review groundbreaking insights from review the 2023 American Society of Hematology Annual Meeting and Exposition (ASH 2023) and discuss the paradigm shift in myeloma frontline treatments, exploring quads, bispecifics, and the dynamic evolution of therapeutic approaches.